Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ebglyss, lebrikizumab-lbkz
Synonyms :
Lebrikizumab
Class :
Interleukin Inhibitors
Brand Name :
Ebglyss, lebrikizumab-lbkz
Synonyms :
Lebrikizumab
Class :
Interleukin Inhibitors
Adult
Solution
250mg/2ml
Administer an initial dose of 500 mg through subcutaneous route at weeks 0 and 2 then start dose of 250 mg every 2 weeks until week 16
Administer a maintenance dose of 250 mg through subcutaneous route every 4 weeks
Dose Adjustments
It may be use with or without topical corticosteroids
Solution
250mg/2ml
For <12 years old: Safety and efficacy not established
For ≥12 years old and ≥40 kg:
Administer an initial dose of 500 mg through subcutaneous route at weeks 0 and 2 then start dose of 250 mg every 2 weeks until week 16
Administer a maintenance dose of 250 mg through subcutaneous route every 4 weeks
Lebrikizumab is monoclonal antibody that targets IL-13 in inflammatory response. It blocks IL-13 receptor to reduce inflammation signalling on cells.
Frequency defined:
>10%
Conjunctivitis
1-10%
Injection site reactions
Herpes zoster
<1%
Vernal keratoconjunctivitis
Keratitis
Eosinophilia
Atopic keratoconjunctivitis
None
Hypersensitivity
Cautions:
Conjunctivitis and keratitis
Parasitic infections
Vaccinations
Pregnancy category: Â N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Lebrikizumab does not block IL-13 binding thus it enables IL-13 internalization through IL-13 receptor alpha-2. The increased dose result in stronger IL-13 activity inhibition effects.
It reduces blood and tissue eosinophil levels, thus known as potential efficacy biomarker.
Pharmacodynamics:
The decreases in type-2 inflammation mediators suggest IL-13 pathway inhibition. IL-13 inhibition enhances skin barrier to reduce hyperplasia and improve integrity. It also reduced the levels of serum periostin and total immunoglobulin E.
Pharmacokinetic:
Absorption:
It is absorbed into the systemic circulation and shows bioavailability up to 86%.
Distribution:
It has moderate volume of distribution as 4.14 L throughout the body.
Metabolism:
Metabolism studies for lebrikizumab are not completed due to its protein nature.
Excretion and elimination:
It has half-life of 24.5 days and clearance up to 0.154 L daily.
Administration:
It is administered subcutaneously in the injection form.
Patient information leaflet:
Generic Name: Lebrikizumab
Why do we use Lebrikizumab?
Lebrikizumab is indicated in the treatment of atopic dermatitis.
It is effective in adults and adolescents from >12 years old with minimum 40 kg body weight.
It is used to reduces skin inflammation, itching, and skin lesions.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
